Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LFCR with free AI briefings, catalyst countdowns, and dilution alerts.

LFCR · LIFECORE BIOMEDICAL, INC. \DE\

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$23M Cash on Hand
CF+ Cash Runway
Follow LFCR by email Get an email when LFCR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LFCR, unsubscribe in one click. Privacy

📣 What LFCR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

LFCR holds $23M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LFCR files for a raise →

👥 Who Owns LFCR

Insiders 44.1% Other 5%+ holders 25.6% Institutions (144 holders) 30.3% Public and other holders 0%
HolderTypeShares% of sharesAs of
Legion Partners Holdings, LLC 5%+ holder (13D) 6,991,919 18.45% 2026-09-27
Nelson Obus
Director
Insider 5,512,210 14.54% 2026-09-27
WYNNEFIELD PARTNERS SMALL CAP VALUE LP I
10% owner
Insider 4,703,216 12.41% 2024-10-03
Christopher S Kiper
Director, 10% owner
Insider 4,507,236 11.89% 2026-06-04
22NW Fund, LP 5%+ holder (13D) 2,712,472 7.16% 2026-06-30
BlackRock, Inc. Institution (13G, 5%+) 2,010,546 5.30% 2026-06-30
Paul Josephs
Chief Executive Officer, Director · +1.35M options
Insider 592,915 1.56% 2026-05-20
Ryan David Lake
Chief Financial Officer · +600,000 options
Insider 336,691 0.89% 2025-09-03
Aron R. English
10% owner
Insider 264,180 0.70% 2025-05-23
Thomas D. Salus
Chief Legal & Administration · +543,000 options
Insider 246,333 0.65% 2026-04-14
Lovas Katrina Houde
Director
Insider 135,319 0.36% 2026-06-04
Joshua Schechter
Director
Insider 133,080 0.35% 2026-06-04

Share count 37,905,846 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full LFCR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LFCR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.